ORALE TESTOSTERON-UNDECANOAT-THERAPIE

European patent · EP3544614 · In force

Register entry

Publication number
EP3544614
Application number
EP17874365
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Nov 28, 2017
Published
Oct 2, 2019
Granted
Dec 31, 2025
Protection ends at the latest
Nov 27, 2037
Next annual fee due
Nov 30, 2026
IPC classes
A61K 31/568 (2006.01)
A61K 9/48 (2006.01)
A61P 5/26 (2006.01)
A61K 31/575 (2006.01)
A61K 9/00 (2006.01)
Priority
US 201662427103 P 28.11.2016
US 201662428336 P 30.11.2016
US 201762442612 P 05.01.2017
PCT application
PCT/US2017/063535 28.11.2017
PCT publication
WO2018/098501 31.05.2018
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Apr 1, 2026

    Agent entered

    Representative
    Vossius & Partner, Patentanwälte Rechtsanwälte mbB, Hirschgässlein 11, 4051 Basel

    Published in Swissreg on 01.04.2026

  2. Dec 31, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 31.12.2025

Parties

Holder

Lipocine Inc.

675 Arapeen Drive Suite 202, Salt Lake City, UT 84108, US

Agent

Vossius & Partner Patentanwälte Rechtsanwälte mbB

Hirschgässlein 11, 4051 Basel

Inventor

CHIDAMBARAM, Nachiappan

Sandy, Utah 84070, US

NACHAEGARI, Satish Kumar

Holladay, Utah 84117, US

PATEL, Mahesh V.

Salt Lake City, Utah 84124, US

KIM, Kilyoung

Salt Lake City, Utah 84108, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.